And One Step Back

Source: Lange DJ, et al. Selegiline is ineffective in a collaborative double-blind, placebo-controlled trial for treatment of amyotrophic lateral sclerosis. Arch Neurol 1998;55:93-96.

Antioxidants have been proposed to be of potential benefit in ALS, particularly since the discovery of the superoxide dismutase mutation in the familial variant (Nature 1993;362:59-62). Sadly, of 133 patients with ALS randomized to receive selegiline (Eldepryl), a monoamine oxidase-B inhibitor with antioxidant properties, 5 mg po bid, or placebo for six months, no significant benefit appeared in the treatment group with respect to rate of disease progression, as measured by the Appel ALS score, or in survival. -mr